Exposure of the elderly to potential nephrotoxic drug combinations in Belgium

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 1014-1019

  Smets, Hilde L E ^a   De Haes, Johan F F ^b   De Swaef, André ^b,c   Jorens, Phillippe G ^d   Verpooten, Gert A ^a,d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b National Institute for Health and Disability Insurance   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

ACEI; ARB; Elderly; Nephrotoxicity; NSAID

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

AGE DISTRIBUTION; AGED; ARTICLE; BELGIUM; CONTROLLED STUDY; DRUG UTILIZATION; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; NEPHROTOXICITY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BELGIUM; COHORT STUDIES; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; MALE; RISK FACTORS; SPIRONOLACTONE;

EID: 57649170612     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1641     Document Type: Article

References (36)

1. Baraldi A, Ballestri M, Rapana R, et al. Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 1998; 13 (Suppl 7): 25-29 [in French].
2. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angio-tensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110(6): 438-441.
3. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation study. N Engl J Med 2004; 351(6): 543-551.
4. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138(11): 917-924.
5. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-2113.
6. Bridoux F, Hazzan M, Pallot JL, et al. Acute renal failure after the use of angiotensin-converting enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100-104.
7. Mandall AK, Markert RJ, Saklayen MG, Mankus RA, Yokokawa K. Diuretics potentiate angiotensine converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 1994; 42: 170-174.
8. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 2002; 90: 663-665.
9. Svensson M, Gustafsson F, Galatius S. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. Br Med J 2003; 327: 1141-1142.
10. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich J, Neumann K. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. Br Med J 2003; 327: 147-149.
11. Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001; 94(10): 512-514.
12. Pharmanet (in Dutch) [online]. Available from URL: http://www.riziv.fgov.be/drug/nl/statistics-scientific-information/ pharmanet/guide/index.htm [accessed 18 February 2008].
13. About the ATC-DDD system [online]. Available from URL: http://www.whocc.no/atcddd/atcsystem.html#6 [accessed 18 February 2008].
14. U.S. Census Bureau, International Data Base. Structure of the Belgian population (2005) (in Dutch) [online]. Available from URL: http://statbel.fgov.be/figures/d21_nl.asp#1 [accessed 18 February 2008].
15. Cronin RE, Henrich WL. Toxic nefropathy. In The Kidney (5th edn), Brenner BM (ed.). W.B. Saunders Co.: Philadelphia, 1996; 1680-1711.
16. Gansevoort R, SluiterW, Hemmelder M, De Zeeuw D, De Jong P. Antiproteinuric effects of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974.
17. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50: 1659-1666.
18. Philbin EF, Santella RN, Rocco TA, Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc 1999; 47: 302-308.
19. Palmer BF. Managing hyperkalemia caused by inhibitors of the Renin-Angiotensin-Aldosterone-system. N Engl J Med 2004; 351: 585-592.
20. Cohn JN, Tognoni G. A randomised clinical trial of the angio-tensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
21. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensine II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
22. McMurray J, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
23. Pfeffer M, McMurray J, Velazquez E, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure. N Eng J Med 2003; 341: 709-717.
24. Masoudi FA, Havrnanek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrolment criteria for clinical trials in heart failure patients. Am Heart J 2003; 146: 250-257.
25. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83(5): 505-510.
26. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki ageing study. J Intern Med 1997; 241(5): 387-394.
27. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam study. Eur Heart J 1999; 20(6): 447-455.
28. Beck LH. The aging kidney. Defending a delicate clearance from serum creatinine. Geriatrics 2000; 55: 26-28; 31-32.
29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
30. Whelton A, Sturmer T, Porter A. Non-steroidal anti-inflammatory drugs. In Clinical Nephrotoxins - Renal Injury From Drugs and Chemicals (2nd edn), De Broe ME, Porter GA, Bennett WM, Verpooten GA (eds). Kluwer Academic Publisher: Dordrecht (The Netherlands), 2003; 279-306.
31. Whelton A. Renal effect over-the-counter analgesics. J Clin Pharmacol 1995; 35: 454-463.
32. Evans JMM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995; 88: 551-557.
33. Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496.
34. Badid C, Chambrier C, Aouifi A, Boucaud C, Bouletreau P. Nonsteroidal anti-inflammatory agent and angiotensin converting enzyme inhibitor: a dangerous combination during postoperative period. Ann Fr Anesth Réanim 1997; 16: 55-57 [in French].
35. Kurata C, Uehara A, Sugi T, Yamazaki K. Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors. Jap Circ J 1999; 63: 1002-1003.
36. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J 1990; 83: 1144-1148.